{
    "nct_id": "NCT04131426",
    "official_title": "Evaluating the Effects of Dietary Supplementation With Remune on Cancer Associated Weight and Muscle Loss With and Without Exercise: A Randomized Pilot Feasibility Study.",
    "inclusion_criteria": "* Be over the age of 18 years and have a primary diagnosis of colorectal, esophageal, gastric, pancreatic, biliary tract cancer (includes cholangiocarcinoma, gallbladder cancer, and ampullary cancer), or Non-small cell lung cancer (NSCLC) with plans to initiate systemic chemotherapy, targeted therapy or immunotherapy within the next 4 weeks after enrollment.\n* Have been diagnosed as having an unresectable cancer with no plans for surgical intervention during the active study period (12 weeks).\n* Have an ECOG performance score of 0 or 1.\n* Have a life expectancy of >3 months as determined by their primary oncologist.\n* Have experienced at least 2% weight loss of the patient's reported previous body weight over the 6 months prior to enrollment.\n* Have permission from primary oncologist to engage in low to moderate intensity exercise regimen.\n* Be able to read English (since the assessment materials are in printed format).\n* Be able to give written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have any of the following limitations: unable to perform low-to-moderate intensity exercise regimen.\n* Have had major surgery (excluding diagnostic procedures like laparoscopy, EGD/EUS, esophageal stent placement) in the past 4 weeks.\n* Be experiencing dysphagia that requires enteral or parenteral feeding for nutrition.\n* Be enrolled on hospice at time of consent.\n* Be engaged in an active exercise routine by being identified as in the Active or Maintenance Stage of exercise behavior as assessed by the 1-item Exercise Stages of Change Short Form (67).\n* Use of nutritional supplements containing EPA/DHA within 2 weeks prior to screening\n* Current Use of Vitamin D supplementation or St. John's wort that can influence efficacy and safety parameters. Chronic treatment (>12 weeks prior to screening) with multivitamin tablets is allowed (vitamin tablets must not contain more vitamin D than 150% of the recommended dietary allowance [RDA]).\n* Known hypersensitivity or allergy to any of the study products. Specifically, patients allergic to milk, fish or shellfish will be excluded.\n* Have AST/ALT >3x upper limit of normal (ULN) or >5xULN in those with liver metastases, Serum creatinine >2x ULN, Absolute Neutrophil Count <1,500/uL, Hemoglobin <9, Platelet count <75,000/uL at the time of baseline blood draw or any other Blood chemistry or hematology lab abnormalities that would exclude them from being able to receive standard chemotherapy or interventional clinical trial.\n* Have uncontrolled Diabetes Mellitus as determined by primary oncologist or PI.",
    "miscellaneous_criteria": ""
}